Dr James Wade, Program Manager for Research and Development discusses recent results from our definitive Mode of Action studies and its importance for Bio-Gene.
📑Read the full @ASX announcement: https://t.co/pgJN09NxKX
$BGT
✔️ We are pleased to announce successful completion of additional mode of action studies.
These results will support a new class of chemistry application with IRAC, a specialist technical group of @CropLifeIntl
📑 Read the full @ASX announcement: https://t.co/pgJN09NxKX
$BGT
Bio-Gene is extremely pleased to announce the appointment of Mr. James Joughin as a Non-executive Director and Chairman of our Audit and Risk Committee.
James is a highly experienced ASX listed and private company Director.
📑 @ASX announcement: https://t.co/p8cI33s2xZ
$BGT
Bio-Gene is pleased to present its financial results for the six months ended 31 December 2020 and an overview of operations for the period.
During the period the Company achieved several key milestones.
📑 Read the full @ASX Announcement here: https://t.co/1CGLiM0YDq
$BGT